Skip to content

Validation of the Zigzag Tracking Task Test for the Evaluation of Handwriting Difficulties in Writer's Cramp

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02882295
Acronym
LabyDys
Enrollment
23
Registered
2016-08-29
Start date
2016-07-05
Completion date
2017-11-15
Last updated
2022-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dystonic Disorder

Brief summary

Writer's cramp (WC) is a task specific dystonia that occurs from the moment patient starts writing. It leads to partial or complete inability to use the hand only during the handwriting gesture. It is characterized by the appearance of cramps or spasms of certain muscles of the hand and/or forearm. Clinical scales currently use for the assessment of WC fail to accurately reflect changes in the characteristics of handwriting in response to treatments (Botulinum Neurotoxin injections and / or retraining therapy). The Zigzag Tracking Task (ZZTT), easy to use in current practice provides useful information in terms of speed and precision of handwriting gesture. This timed handwriting test is to follow with a pen a zigzag path beset with obstacles to avoid. It permits to evaluate the time in seconds required to carry out the zigzag path and count the number of errors (output path and contacts with obstacles). The investigators propose to validate the ZZTT for the assessment of the handwriting gesture of WC.

Interventions

OTHERValidation of a handwriting scale

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* scholarship in French language, at least until 16 years old * writer's cramp (diagnostic confirmed by a neurologist specialized in movement disorders) * prescription of botulinum neurotoxin injection * prescription de novo or absence of injection in the last 3 months * informed consent * medical insurance coverage

Exclusion criteria

* writing tremor * -other neurological disease with effect on handwriting * pain or traumatism of the upper limb, with effect on handwriting * non-corrected visual disturbances * patient living outside the region where the study will be held (Ile-de-France) * participation in another research with a potential impact on evaluation criteria * pregnant or breast feeding patient * patient under judiciary protection

Design outcomes

Primary

MeasureTime frameDescription
hand-writing speedimmediatespeed and accuracy of handwriting

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026